Intetumumab is a monoclonal antibody targeting integrin αV (ITGAV or CD51), which plays a key role in cell adhesion, migration, and signaling in various pathological processes. It has been investigated primarily for its potential in cancer therapy due to its ability to inhibit tumor angiogenesis and metastasis. By blocking αV-containing integrins, intetumumab disrupts the interaction between tumor cells and the extracellular matrix, thereby suppressing tumor growth and spread. The antibody has shown promise in preclinical and early clinical studies for solid tumors, including melanoma, prostate cancer, and glioblastoma. It may enhance the effects of chemotherapy and radiation by normalizing tumor vasculature and improving drug delivery. Additionally, intetumumab is used as a research tool to study integrin-mediated signaling pathways in inflammation, fibrosis, and wound healing. Its specificity makes it valuable in diagnostic and therapeutic development involving αV integrin expression in diseased tissues.